Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy

Objective: To evaluate the effects of isoflavones on vasomotor symptoms and blood lipids in postmenopausal women with contraindication for conventional hormone replacement therapy (HRT). Methods: This prospective, double-blind and placebo-controlled study included 50 postmenopausal women randomly di...

Full description

Saved in:
Bibliographic Details
Published in:Maturitas 2004-08, Vol.48 (4), p.372-380
Main Authors: Petri Nahas, Eliana, Nahás Neto, Jorge, De Luca, Laurival, Traiman, Paulo, Pontes, Anaglória, Dalben, Ivete
Format: Article
Language:English
Subjects:
Biological and medical sciences
Brazil
Cholesterol, HDL - blood
Cholesterol, LDL - blood
Diet
Double-Blind Method
Estradiol - blood
Female
Follicle Stimulating Hormone - blood
Follicle Stimulating Hormone - metabolism
Genital system. Reproduction
Gynecology. Andrology. Obstetrics
Hormone Replacement Therapy
Hot flushes
Humans
Isoflavone
Isoflavones - pharmacology
Lipid profile
Luteinizing Hormone - blood
Medical sciences
Menopause
Pharmacology. Drug treatments
Placebos
Postmenopause - blood
Postmenopause - drug effects
Postmenopause - physiology
Prospective Studies
Puberal and climacteric disorders (male and female)
Soy Foods
Soy germ
Time Factors
Triglycerides - blood
Vasomotor System - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To evaluate the effects of isoflavones on vasomotor symptoms and blood lipids in postmenopausal women with contraindication for conventional hormone replacement therapy (HRT). Methods: This prospective, double-blind and placebo-controlled study included 50 postmenopausal women randomly divided into two groups: 25 women on soy germ isoflavones (60 mg per day, capsules) and 25 women on placebo. Inclusion criteria included: non-vegetarian, non-asian women whose last menstruation dated at least 12 months prior to the beginning of the study, with FSH>40 mIU/ml, hot flushes and contraindication for HRT, not using tamoxifen or antibiotic and no disease of the gastrointestinal tract. For 6 months, the Kupperman menopausal index (KMI), the vaginal cytological maturation value (MV) and both hormonal and lipid profiles were assessed. The t-test and analysis of variance (ANOVA) were employed to compare the two groups. Results: In both groups, a decreased KI rate was observed. However, isoflavone was significantly superior to placebo in reducing hot flushes (44% versus 10%, respectively) ( P
ISSN:0378-5122
1873-4111
DOI:10.1016/j.maturitas.2003.09.026